Skin testing and desensitization outcomes among platinum-sensitive oncology patients

Platinum-based, immediate hypersensitivity reactions (HSRs) are relatively common, with incidences ranging from 6.5% to 44% for carboplatin and from 10% to 19% for oxaliplatin.1 Platinum hypersensitivity potentially leads to patient anxiety, delayed chemotherapy administration, or switches to less-preferred regimens. Platinum skin tests (STs) confirm immediate-type reactions in upward of 66%–98% of patients.2–5 False-negative results may occur if ST is performed shortly after a platinum-based HSR.

https://ift.tt/2JfJW9p